JAZZ Earnings & Financial Statements
Jazz Pharmaceuticals plc
$216.75
-$1.67(-0.76%)
55
Overall
60
Value
45
Tech
60
Quality
Market Cap
$14.18B
Volume
739.60K
52W Range
$128.80 - $266.38
Target Price
$295.64
JAZZ earnings and financial statements: Jazz Pharmaceuticals plc's income statement, balance sheet and cash flow statement, annual and quarterly.
JAZZ Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $4.27B | $4.07B | $3.83B | $3.66B | $3.09B |
| Cost of revenue | $503.30M | $445.71M | $435.58M | $540.52M | $440.76M |
| Operating income | -$430.24M | $716.63M | $578.58M | -$65.53M | $170.28M |
| EBITDA | $262.76M | $1.37B | $1.22B | $535.01M | $718.41M |
| Net income | -$356.15M | $560.12M | $414.83M | -$224.06M | -$329.67M |
| EPS (diluted) | $-5.84 | $8.65 | $6.10 | $-3.58 | $-5.52 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $11.66B | $12.01B | $11.39B | $10.84B | $12.30B |
| Total liabilities | $7.34B | $7.92B | $7.66B | $7.75B | $8.33B |
| Shareholders’ equity | $4.32B | $4.09B | $3.74B | $3.09B | $3.97B |
| Cash and equivalents | $1.39B | $2.41B | $1.51B | $881.48M | $591.45M |
| Long-term debt | $4.38B | $6.12B | $5.17B | $5.77B | $6.11B |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | $1.36B | $1.40B | $1.09B | $1.27B | $778.51M |
| Capital expenditure | -$139.09M | -$38.07M | -$42.96M | -$498.19M | -$45.53M |
| Free cash flow | $1.19B | $1.36B | $1.07B | $773.78M | $732.98M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | JAZZ | $216.75 | -0.8% | 739.60K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Jazz Pharmaceuticals plc Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW